{
    "nct_id": "NCT06752681",
    "official_title": "A Phase 1, Open Label, Multiple Dose, Dose Escalation and Expansion Study to Investigate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of the PTK7-Targeted Antibody-drug Conjugate DAY301 in Patients With Locally Advanced or Metastatic Solid Tumors",
    "inclusion_criteria": "* Patients with histologically or cytologically confirmed diagnosis of advanced or metastatic solid tumors of the following histologies:\n* Ovarian cancer\n* Esophageal squamous cell carcinoma\n* Triple-negative breast cancer\n* Non-small cell lung cancer\n* Small cell lung cancer\n* Head and neck squamous cell carcinoma\n* Gastric/gastroesophageal junction adenocarcinoma\n* Cervical squamous cell carcinoma\n* Endometrial cancers\n\n(Patients must have been previously treated with standard of care systemic therapy, or for whom no standard therapy is available).\n\n* Availability of tumor tissue sample (either an archival specimen or a fresh biopsy) at screening\n* Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST v1.1).\n* ECOG performance status of 0 or 1.\n* Adequate organ function.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Prior use of PTK7 targeting treatment.\n* Active or progressing brain metastases or evidence of leptomeningeal disease.\n* Persistent toxicities from previous systemic antineoplastic treatments of Grade >1, excluding alopecia and vitiligo.\n* Systemic antineoplastic therapy within 5 half-lives or 4 weeks, whichever is shorter, prior to first dose of the study drug, including investigational agents.\n\nNote: Other protocol defined Inclusion/Exclusion criteria may apply.",
    "miscellaneous_criteria": ""
}